The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid
Table 3
Fatty acid content of red blood cell membranes in healthy volunteers (HV) and inflammatory bowel disease (IBD) patients.
Fatty acid
Baseline
2 weeks
4 weeks
8 weeks
Change in fatty acid content from baseline to week 8*
%CV
HV
n-6 PUFAs
C18:2 LA
10.5 ± 1.4**
9.1 ± 1
7.7 ± 1
6.5 ± 1
−4.0 (−4.5 to −3.5)***
24.0
C20:4 AA
14.5 ± 0.7
12.2 ± 1.2
10.1 ± 0.7
9.7 ± 0.6
−4.8 (−5.2 to −4.3)
17.9
n-3 PUFAs
C20:5 EPA
0.3 ± 0.1
1.7 ± 0.4
4 ± 0.5
4.5 ± 0.4
4.3 (4.0 to 4.5)
9.8
C22:5 DPA
0.8 ± 0.2
1.4 ± 0.4
2.2 ± 0.4
3.8 ± 0.7
2.9 (2.5 to 3.4)
27.3
C22:6 DHA
3 ± 0.5
3.3 ± 0.5
3.6 ± 0.7
4.2 ± 0.8
1.2 (0.7 to 1.7)
69.4
IBD
n-6 PUFAs
C18:2 LA
12.2 ± 1°
11.1 ± 0.8
9.7 ± 0.8
7.8 ± 0.8
−4.4 (−4.8 to −3.9)
20.4
C20:4 AA
18 ± 2.1°
15.7 ± 1.9
14.1 ± 1.7
11.6 ± 1.5
−6.5 (−7.4 to −5.5)
31.0
n-3 PUFAs
C20:5 EPA
0.2 ± 0.1
1.1 ± 0.3
2.1 ± 0.4
4.3 ± 0.7
4.1 (3.7 to 4.4)
16.3
C22:5 DPA
0.4 ± 0.1
1.1 ± 0.6
2.2 ± 0.5
3.3 ± 0.4
2.8 (2.6 to 3.0)
15.5
C22:6 DHA
3.1 ± 0.5
3.7 ± 0.4
4.5 ± 0.4
5 ± 0.4
1.9 (1.6 to 2.2)
33.5
Values are mean ± SD. for the difference in individual n-3 PUFA content between IBD patients and HV. *Absolute change in % fatty acid content. ***Data are the mean and 95% confidence interval. All ≤ 0.01. PUFAs: polyunsaturated fatty acids. LA: linoleic acid. AA: arachidonic acid. EPA: eicosapentaenoic acid. DPA: docosapentaenoic acid. DHA: docosahexaenoic acid. CV: coefficient of variation.